Pfizer plans to ask US regulators to authorize a booster dose of its COVID-19 vaccine within the next month, the drugmaker's top scientist said on Thursday, according to Reuters.
The move is based on evidence of greater risk of reinfection six months after inoculation and due to the spread of the highly contagious Delta variant.
Read more